The place of drug therapy in up-to-date arrhythmology (from the results of the EHRA 2023 congress to national clinical practice)

References

• 1. Savelieva I., Fumagalli S., Kenny R.-A., et al. (2023) EHRA expert consensus document on the management of arrhythmias in frailty syndrome, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). EP Europace, 25(4): 1249–1276. doi.org/10.1093/europace/euac123.
• 2. Burri H., Jastrzebski M., Cano O. et al. (2023) EHRA clinical consensus statement on conduction system pacing implantation: endorsed by the Asia Pacific Heart Rhythm Society (APHRS), Canadian Heart Rhythm Society (CHRS), and Latin American Heart Rhythm Society (LAHRS). EP Europace, 25(4): 1208–1236. doi.org/10.1093/europace/euad043.
• 3. Chen L.Y., Chung M.K., Allen L.A. et al.; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Stroke Council (2018) Atrial Fibrillation Burden: Moving Beyond Atrial Fibrillation as a Binary Entity: A Scientific Statement From the American Heart Association. Circulation, 137(20): e623–e644. doi.org/10.1161/CIR.0000000000000568.
• 4. Bergonti M., Spera F., Tijskens M. et al. (2022) A new prediction model for left ventricular systolic function recovery after catheter ablation of atrial fibrillation in patients with heart failure: The ANTWOORD Study. Int. J. Cardiol., 358: 45–50. doi.org/10.1016/j.ijcard.2022.04.040.
• 5. Tilz R.R., Schmidt V., Pürerfellner H. et al. (2023) A worldwide survey on incidence, management, and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: the POTTER-AF study. Eur. Heart J., ehad250. doi.org/10.1093/eurheartj/ehad250.
• 6. Kirchhof P., Breithardt G., Eckardt L. (2006) Primary prevention of sudden cardiac death. Heart (British Cardiac Society), 92(12): 1873–1878. doi.org/10.1136/hrt.2006.087957.
• 7. Lei M., Wu L., Terrar D.A., Huang C.L.-H. (2018) Modernized Classification of Cardiac Antiarrhythmic Drugs. Circulation, 138(17): 1879–1896.
• 8. Huang J., Wu M.Z., Ren Q.W. et al. (2023) Statin use improves the outcomes in patients with atrial fibrillation: A population-based study. esc365.escardio.org/presentation/261061?query=statins%20AF%20stroke.
• 9. Stiavnicky P., Wichterle D., Jansova H. et al. (2023) Radiofrequency catheter denervation of sinus node by targetting the right anterior ganglionated plexus: towards minimizing the lesions set. esc365.escardio.org/presentation/261299.
• 10. Piotrowski R., Zuk A., Baran J. et al. (2023) Cardioneuroablation for asystolic reflex syncope­left or right atrial approach? A randomized prospective Roman II study: ­preliminary results. esc365.escardio.org/presentation/260992.
• 11. Piotrowski R., Baran J., Sikorska A. et al. (2023) Cardioneuroablation for Reflex Syncope: Efficacy and Effects on Autonomic Cardiac Regulation-A Prospective Randomized Trial. JACC. Clin. Electrophysiol., 9(1): 85–95. doi.org/10.1016/j.jacep.2022.08.011.
• 12. Алипов Н.Н. (2008) Основы медицинской физиологии. Практика, Москва, с. 95–96.
• 13. Feigofsky S., Fedorowski A. (2020) Defining Cardiac Dysautonomia — Different Types, Overlap Syndromes; Case-based Presentations. Journal of atrial fibrillation, 13(1): 2403. doi.org/10.4022/jafib.2403.
• 14. Owens A.P., Low D.A., Iodice V. et al. (2017) The genesis and presentation of anxiety in disorders of autonomic overexcitation. Autonomic neuroscience: basic & clinical, 203: 81–87. doi.org/10.1016/j.autneu.2016.10.004.
• 15. Carmona-Torre F., Mínguez-Olaondo A., López-Bravo A. et al. (2022) Dysautonomia in COVID-19 Patients: A Narrative Review on Clinical Course, Diagnostic and Therapeutic Strategies. Front. Neurol., 13. doi.org/10.3389/fneur.2022.886609.
• 16. Сидорова Н.М. (2021) Оновлення класифікації антиаритмічних засобів: королівський гамбіт для дослідників та практиків? Аналітичний огляд літератури. Сучасні аспекти військової медицини, 28(2): 214–235. doi.org/10.32751/2310-4910-2021-28-2-18.
• 17. Linz B., Thostrup A.H., Saljic A. et al. (2020) Pharmacological inhibition of acetylcholine-regulated potassium current (IKACh) and associated A₁— and M₂-pathways prevent atrial arrhythmogenic changes in a rat model for obstructive sleep apnea. Eur. Heart J., 41(Suppl. 2): ehaa946.3701. doi.org/10.1093/ehjci/ehaa946.3701.
• 18. Linz B., Hertel J.N., Sattler S.M. et al. (2022) Sympatho-vagal activation during obstructive respiratory events in pigs and blunted atrial arrhythmogenic effects by pharmacological IKACh-inhibition. esc365.escardio.org/presentation/246340.
• 19. Коваленко В.М., Лутай М.І., Сіренко Ю.М., Сичов О.С. (ред.) (2021) Серцево-судинні захворювання. Класифікація, стандарти діагностики та лікування. 5-те вид., переробл. і доповн. Моріон, Київ, с. 239–240.
• 20. Попова Е.П., Лысковцев В.В., Каверина Н.В. (2005) Электрофизиологические эффекты и антиаритмическое действие препаратов I класса этмозина и этацизина в условиях активации парасимпатической нервной системы. Вест. аритмол., (37): 57–61.
• 21. Kokina B., Strēlnieks A., Pupkeviča I. et al. (2021) Sinus Rhythm Maintenance After Electrical Cardioversion for Atrial Fibrillation in High-Risk Patients — Comparative Efficacy of Antiarrhythmic Medications. Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences, 75(1): 32–39. doi.org/10.2478/prolas-2021-0006.
• 22. Sydorova N. (2023) Class Ic antiarrhythmic drugs: informed choice. Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences, 77(2): 20–30. DOI: 10.2478/prolas-2023-00XX.